Please login to the form below

Not currently logged in
Email:
Password:

allergies

This page shows the latest allergies news and features for those working in and with pharma, biotech and healthcare.

FDA moves into crisis mode as shutdown drags on

FDA moves into crisis mode as shutdown drags on

allergy therapy AR101 until after government starts operating again.

Latest news

More from news
Approximately 11 fully matching, plus 177 partially matching documents found.

Latest Intelligence

  • Asthma: beyond the blue and the brown Asthma: beyond the blue and the brown

    for prevention of cat and ragweed allergies.

  • Deal Watch July 2016 Deal Watch July 2016

    And Finally, Reality Bites. ALK-Abello has issued a press release announcing that Merck &Co has walked away from the deal agreed in 2007 (with Schering-Plough) for the allergy treatments ... Grastek and Ragwitek are sublingual allergy immunotherapy (SLIT)

  • Allergies and asthma Allergies and asthma

    The safest way to manage allergy symptoms is to tackle them before they set in. ... of the hypo-allergenic milk formula on cow's milk allergy and atopic dermatitis (AD).

  • Coming to an understanding Coming to an understanding

    We derived greater insight and intelligence.”. A similar process on the composition of an allergy panel for product testing had the physicians working in groups to devise their 'panel of the

  • Deal Watch February 2016 Deal Watch February 2016

    Annapurna brings a portfolio of four AAV-based gene therapy programmes at the preclinical stage for alpha-1 antitrypsin deficiency, hereditary angioedema, cardiomyopathy associated with Friedreich's ataxia and severe allergy.

More from intelligence
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest appointments

  • ALK-Abello appoints Søren Jelert as CFO ALK-Abello appoints Søren Jelert as CFO

    He will be based at the company’s headquarters in Denmark. Dansih allergy immunotherapy company ALK-Abello has appointed Søren Jelert as its new chief financial officer, a role that sees ... to become a truly global allergy company.”.

  • Cytovation expands management team Cytovation expands management team

    Grego is currently chief executive officer of Spire Bioventures, a global healthcare consultancy and mentoring service, and has previously held a number of management positions at Spanish allergy specialist Laboratorios LETI.

  • Lars Dreiøe joins Sobi in senior quality and compliance role Lars Dreiøe joins Sobi in senior quality and compliance role

    He will join the firm in January from Danish allergy vaccine company ALK Abelló, where he was international head of quality.

  • ARC names chairman and member of the board ARC names chairman and member of the board

    ARC is a privately held biopharma company developing desensitisation treatments for food allergies. ... Iwicki said: “ARC is working to address a very compelling therapeutic area and provide an option to those dealing with food allergies.

  • Insmed appoints FDA's Dr Eugene Sullivan Insmed appoints FDA's Dr Eugene Sullivan

    He also spent a seven-year spell from 1999 at the FDA, where he held several positions, including deputy director of its Pulmonary and Allergy Products division.

More from appointments
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics